Mexico Schizophrenia Drugs Market Size & Forecast 2025–2033

According to Renub Research Recent Report Mexico Schizophrenia Drugs Market is projected to reach US$ 196.45 million by 2033, growing from US$ 148.99 million in 2024 at a CAGR of 3.12% during 2025–2033. The market is driven by the increasing incidence of schizophrenia and related mental health disorders, along with improved awareness, government initiatives, and expanding access to modern treatments.

Market Overview

The schizophrenia drugs market in Mexico is expanding steadily as mental health awareness improves and treatment accessibility increases. Second-generation antipsychotics (SGAs), such as risperidone, olanzapine, and quetiapine, are increasingly prescribed due to their better safety profiles and reduced risk of side effects like tardive dyskinesia, despite their higher costs compared to first-generation drugs.

Challenges in the Mexican healthcare system, including fragmented distribution networks, intermittent drug shortages, and limited psychiatric care in rural areas, restrict continuous treatment. Opportunities are emerging through telepsychiatry, growth in generics, and faster regulatory approvals, which may enhance availability and affordability.

Government initiatives, rising healthcare expenditure, and a growing patient base support market growth. The Mexican Institute of Social Security (IMSS) estimates that over 1.8 million people are affected by schizophrenia or other psychotic disorders. Mental health disorders contribute nearly 12% of the nation’s total disability-adjusted life years (DALYs).

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Key Market Growth Drivers

1. Growing Prevalence and Mental Health Awareness

Public health education and campaigns are reducing stigma and increasing schizophrenia diagnosis rates. Greater mental health literacy encourages patients to seek early intervention and ongoing treatment, fueling demand for antipsychotic medications.

2. Transition to Second-Generation Antipsychotics (SGAs)

SGAs are preferred by Mexican psychiatrists for their superior efficacy and lower side-effect profile compared to first-generation drugs. Patient adherence improves due to fewer movement-related side effects, and generic SGA availability is gradually increasing. SGAs are becoming the mainstay of schizophrenia treatment in urban and accessible healthcare settings.

3. Growth of Long-Acting Injectables (LAIs)

Long-acting injectable antipsychotics (LAIs) are gaining popularity because they enhance treatment compliance, reduce relapse rates, and maintain steady drug levels. LAIs are particularly effective for patients who struggle with daily oral medication adherence and are increasingly used in public health systems and community psychiatric programs.

Market Challenges

1. High Cost of Second-Generation Antipsychotics

Although clinically effective, SGAs are expensive and not always fully covered by public insurance. Low-income and rural patients face financial barriers, potentially leading to delayed treatment, therapy discontinuation, or suboptimal disease control. Limited availability of affordable generics compounds the challenge.

2. Restricted Access to Psychiatric Care

A shortage of qualified mental health specialists, particularly in rural areas, delays diagnosis and treatment. Overburdened clinics and long wait times, even in urban regions, reduce patient access and monitoring. Gaps in continuity of care highlight the need for telemedicine expansion and enhanced psychiatric training.

Regional Market Overview

Northern Mexico

Key cities: Monterrey, Tijuana, Chihuahua

Northern Mexico has better healthcare infrastructure and urbanization, supporting access to SGAs and LAIs. Public awareness is increasing, but affordability remains a constraint for low-income patients. Investments in regional healthcare and mental health education are needed to improve treatment access.

Central Mexico

Key areas: Mexico City and metropolitan regions

Central Mexico is the largest market due to high concentration of mental health facilities, skilled specialists, and stronger public healthcare systems. Early diagnosis rates are improving, and SGAs and LAIs are more accessible in urban settings. Rural outreach and treatment continuity gaps remain.

Southern Mexico

Key states: Oaxaca, Chiapas, Guerrero

Southern Mexico faces major challenges due to economic disparities, limited healthcare infrastructure, and low mental health awareness. First-generation antipsychotics dominate due to affordability, while LAIs and SGAs remain largely inaccessible. Stigma and lack of qualified professionals hinder treatment adherence. Targeted government interventions and outreach programs are needed to improve access, affordability, and outcomes.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentations

By Treatment

Oral

Injectable

By Therapeutic Class

Second Generation

Third Generation

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

Northern Mexico

Central Mexico

Southern Mexico

Others

Key Players

H. Lundbeck A/S

Pfizer Inc.

AbbVie

AstraZeneca

Bristol Myers Squibb

Eli Lilly

GlaxoSmithKline

Johnson & Johnson

Novartis AG

Takeda Pharmaceuticals

Coverage includes: Company Overview, Key Personnel, Recent Developments, SWOT Analysis, and Revenue Analysis

Conclusion

The Mexico Schizophrenia Drugs Market is expected to grow steadily due to increasing mental health awareness, adoption of SGAs and LAIs, and government initiatives to expand psychiatric care access. Key challenges such as high drug costs, limited psychiatric care in rural areas, and healthcare disparities remain, requiring targeted interventions to improve accessibility, affordability, and continuity of care.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.